For the quarter ended December 2023, AbbVie (ABBV) reported revenue of $14.3 billion, down 5.4% over the same period last year. EPS came in at $2.79, compared to $3.60 in the year-ago quarter.The reported revenue represents a surprise of +1.78% over the Zacks Consensus Estimate of $14.05 billion. With the consensus EPS estimate being $2.76, the EPS surprise was +1.09%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expec ...

Key PointsAbbVie's treatment for patent-cliff woes is working and has the company on track to return to growth soon. Humira continues to outperform, and the non-Humira portfolio is more robust than expected. The pipeline is robust and amplified by recently announced acquisitions expected to close this year. 5 stocks we like better than AbbVieAbbVie NYSE: ABBV is turning an important corner in 2024 and is on track to resume growth. Its Humira-related patent cliff aside, the business is stronger than ever, an ...

The fourth-quarter earnings season is in full swing for the drug and biotech sector.  The performance of the large drugmakers that have reported so far has been rather lukewarm, with most posting mixed results.Higher tax rates due to changes in global tax regulations, concerns around the economy and inflation, regular pipeline setbacks and the slow ramp-up of newer drugs are some concerns of drug developers. Uncertainty about the impact of Medicare drug price negotiations and the Federal Trade Commission’s ...

AbbVie (ABBV) came out with quarterly earnings of $2.79 per share, beating the Zacks Consensus Estimate of $2.76 per share. This compares to earnings of $3.60 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.09%. A quarter ago, it was expected that this drugmaker would post earnings of $2.86 per share when it actually produced earnings of $2.95, delivering a surprise of 3.15%.Over the last four quarters, the company has surpa ...

Pharmaceuticals company AbbVie (NYSE: ABBV) reported its Q4 and full year financial results for 2023 this afternoon.The American medical R&D powerhouse had some setbacks in the year, including disappointing profits from their drug Humira, which lost significant market share to generic knockoffs in both the US and abroad in 2023. Full year resultsCopy link to sectionThe company reported net revenues of $54.318 billion, 6.4 percent less YoY than 2022, and diluted EPS of $2.72 for the full year on a GAAP basis ...

AbbVie Inc. ABBV, +1.94% on Friday reported fourth-quarter sales that topped analysts’ estimates, even as it faces low-cost competition for its top-selling drug, Humira. The drugmaker reported fourth-quarter net income of $822 million, or 46 cents per share, down sharply from $2.473 billion, or $1.38 per share, in the year-earlier period. Adjusted earnings per share of $2.79, which included an unfavorable impact of 15 cents a share related to acquired in-process research and development expenses, matched th ...

Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis, a Decrease of 59.0 Percent; Adjusted Diluted EPS of $11.11, a Decrease of 19.3 Percent; These Results Include an Unfavorable Impact of $0.42 Per Share Related to 2023 Acquired IPR&D and Milestones Expense  Delivers Full-Year Net Revenues of $54.318 Billion, a Decrease of 6.4 Percent on a Reported Basis and 5.9 Percent on an Operational Basis Full-Year Global Net Revenues from the Immunology Portfolio Were $26.136 Billion, a Decrease of 9.6 Percent on ...

There is a lot of good news to digest from the biotech sector. Not only does it offer lots of strong stocks in January, but it is also expected to grow rapidly. Analysts expect compound annual growth approaching 13% between the years 2023 and 2030.There’s a lot going on within the sector that will serve to prompt that growth. Artificial intelligence has important applications to the biotechnology sector. CRISPR gene editing technology continues to evolve  including new applications at the commercial level. ...

-- New report incorporates in-depth interviews, industry research and social listening to understand the role of individuality in the world of aesthetics ---- Report underpins ongoing commitment to aesthetics accessibility and inclusivity to achieve desired patient outcomes --IRVINE, Calif., Jan. 31, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie (NYSE: ABBV) company and a global leader in medical aesthetics treatments, released the "Decoding the Future of Aesthetic Individuality" report, which ...

In its upcoming report, AbbVie (ABBV) is predicted by Wall Street analysts to post quarterly earnings of $2.79 per share, reflecting a decline of 22.5% compared to the same period last year. Revenues are forecasted to be $14.06 billion, representing a year-over-year decrease of 7%.Over the last 30 days, there has been a downward revision of 0.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forec ...